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ABSTRACT
Background Immune checkpoint inhibitor (ICI) can cause 
severe and sometimes fatal immune- related adverse 
events (irAEs). Since these irAEs mimick immunological 
disease, a female predominance has been speculated on. 
Nevertheless, no demographic or tumour- related factors 
associated with an increased risk of irAEs have been 
identified until now.
Methods Risk ratios of severe (grade ≥3) irAEs for age, 
sex, WHO performance status, number of comorbidities, 
stage of disease, number of metastases and serum lactate 
dehydrogenases (LDH) were estimated using data from 
anti- PD1- treated patients with advanced melanoma in the 
prospective nationwide Dutch Melanoma Treatment Registry.
Results 111 (11%) out of 819 anti- programmed cell death 
1 treated patients experienced severe irAEs. Patients with 
non- lung visceral metastases (stage IV M1c or higher) less 
often experienced severe irAEs (11%) compared with patients 
with only lung and/or lymph node/soft tissue involvement 
(stage IV M1b or lower; 19%; adjusted risk ratio (RRadj) 0.63; 
95% CI 0.41 to 0.94). Patients with LDH of more than two 
times upper limit of normal had a non- significantly lower risk 
of developing severe irAEs than those with normal LDH (RRadj 
0.65; 95% CI 0.20 to 2.13). None of the other variables were 
associated with severe irAEs.
Conclusion In patients with melanoma, more advanced 
disease is associated with a lower rate of severe irAEs. No 
association with sex was found.
INTRODUCTION
Through the blockage of programmed cell- 
death 1 (PD-1), the immune checkpoint 
inhibitors (ICIs) nivolumab and pembroli-
zumab reinvigorate tumour- specific T cells, 
potentially resulting in long- lasting antitu-
mour response and increased overall survival 
in several types of malignancies, such as 
advanced melanoma, non- small cell lung 
cancer and renal cell carcinoma.1 2 On the 
other hand, checkpoint inhibition can cause 
immune- related adverse events (irAEs), 
ranging from mild to severe, which can be 
irreversible and in some cases fatal.3
As ICIs are now used as adjuvant treat-
ment, trying to improve cure rates for stage 
III and resected stage IV melanoma and non- 
squamous cell lung cancer, it is becoming 
more and more important to identify patients 
who are at increased risk for severe ICI 
toxicity.
IrAEs mimic autoimmune disease that are 
known to have a female predominance.4 In 
line with that, women might be more prone 
to develop irAEs during checkpoint inhibi-
tion.5 6 In addition, the high toxicity rates in 
early (neo)adjuvant studies have led to the 
hypothesis that irAEs occur more frequently 
in patients with lower tumour load.7
Studies so far investigating determinants of 
anti- PD(L)1 toxicity were of limited sample 
size with a median of 78 patients at risk (IQR 
50–128).8–21 Here we analysed whether demo-
graphic and disease- specific patient charac-
teristics present at start of treatment were 
associated with an increased risk of severe 
irAEs using a large dataset from our nation-
wide melanoma treatment registry.
Key questions
What is already known about this subject?
 ► Immune checkpoint inhibitor can cause severe and 
sometimes fatal immune- related adverse events 
(irAEs). No demographic or tumour- related factors 
associated with an increased risk of irAEs have been 
identified until now.
What does this study add?
 ► This study demonstrates that more advanced dis-
ease is associated with a significant decreased risk 
of severe irAEs in patients with melanoma.
How might this impact on clinical practice?
 ► By improving irAE risk prediction in individual pa-
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METHODS
Patients
The Dutch Melanoma Treatment Registry (DMTR) 
prospectively registers demographic and clinical data 
from all unresectable patients with stage III and IV mela-
noma in the Netherlands since 2012.22 In this report, we 
included all patients who received either nivolumab or 
pembrolizumab monotherapy from 1 July 2012 until 31 
December 2017 as first ICI. Patients who were previously 
treated with ipilimumab or combined ipilimumab plus 
nivolumab were not included in this report to exclude 
the possibility of overlapping toxicity. Patients who were 
censored due to data cut- off within 3 months after treat-
ment initiation were excluded, as they had a substantial 
risk of getting an irAE after censoring.23 Toxicities were 
graded according to the Common Terminology Criteria 
of Adverse Events V.4.03. In the DMTR, only severe irAEs 
are registered (ie, ≥grade 3). In compliance with Dutch 
regulations, the DMTR was approved by the medical 
ethical committee and was not subject to the Medical 
Research Involving Human Subjects Act.
Statistical analyses
Variables age, sex, WHO performance status (0 vs 1 vs ≥2), 
number of comorbidities, stage of disease (American Joint 
Committee on Cancer V.8; unresectable stage III/stage IV 
M1a/M1b vs stage IV M1c/M1d), number of metastatic 
sites (<5 vs ≥5) and serum lactate dehydrogenase (LDH; 
≤upper limit of normal (ULN; 250 U/L) vs 1–2 × ULN vs 
>2 × ULN) at start of treatment were tested for correlation 
with severe irAEs. Furthermore, in a subgroup of patients 
who were solely in stage M1c/M1d, the correlation of 
symptomatic brain metastases with severe irAEs was tested. 
At first, since irAE is a frequently occurring outcome,24 25 
unadjusted risk ratio (RR) of severe irAEs including 95% 
CI was calculated using Poisson regression. Then, multi-
variable Poisson regression analysis was used to calculate 
adjusted RR for each variable, with all other variables and 
follow- up time (time from start of treatment until death/
censoring) as covariate. Both univariable and multivari-
able analyses were performed in treatment- naive patients 
and in patients receiving first ICI treatment irrespective 
of line of systemic treatment (including first line) with 
additional adjustment for line of therapy in the multi-
variable analyses. Significant results were then verified 
in only patients who were alive 3 months after treatment 
initiation to account for time dependency of severe irAEs. 
For multivariable analyses, missing variable data were 
imputed using the mice package in R.26 For each anal-
ysis, a number of imputed datasets were created, corre-
sponding to the percentage of patients in which at least 
one variable was missing (eg, 16 for first- line anti- PD1 and 
18 for all line anti- PD1 therapy).27 Mann- Whitney U test 
was used to test for differences in treatment duration, as 
this was not normally distributed. All analyses were done 
using two- sided tests. P values <0.05 were considered 
significant. R V.3.5.1 was used including dplyr, mice, stats 
and survival packages.
RESULTS
In total, 927 patients receiving nivolumab (n=283) or 
pembrolizumab (n=644) in any line between 2012 and 
2017 were registered. Sixty- two patients were excluded 
because of missing toxicity status. Additionally, 46 patients 
who were censored due to data cut- off within 3 months 
after start of therapy were excluded; the remaining 819 
patients were included in this study. Median follow- up 
after start of treatment was 11 months (IQR 5–17). 
Patients received a median of seven cycles of anti- PD1 
therapy (IQR 3–15). A total of 557 patients were treated 
in first line, 208 were treated in second line, 39 in third 
line and 15 in later lines (table 1).
Among patients treated with anti- PD1 in any line, 111 
(14%) suffered severe (ie, grade ≥3) irAEs. These included 
colitis (n=23; 2.8%), hepatitis (n=14; 1.7%), dermatitis 
(n=13; 1.6%), pneumonitis (n=10; 1.2%), endocrine 
toxicities (n=9; 1.1%), including thyroiditis (n=5; 0.6%) 
and other toxicities (n=56; 6.8%). Four patients died 
because of treatment related grade 5 toxicity. Median 
duration on treatment was 139 days (IQR=58–313) for 
patients with severe irAEs and 105 days (42–252) for 
patients without, which was not significantly different 
(p=0.14). Data on treatment duration were incomplete 
in 8% and 16% of patients with and without severe irAEs.
Patients with stage IV M1c or higher significantly 
less often experienced severe irAEs: 63 (11%)/565, 
compared with 45 (19%)/232 with stage IV M1b or lower 
disease (RR 0.57; 95% CI 0.39 to 0.85; RRadj 0.63; 95% CI 
0.41 to 0.94). Of note, when including solely those 706 
patients who were alive 3 months after treatment initia-
tion, the association remained significant (RRadj 0.65; 
95% CI 0.42 to 0.99). Patients with an LDH ≥2 × ULN had 
a non- significant decreased risk of severe irAEs compared 
with patients with normal LDH (RRadj 0.65; 95% CI 0.20 
to 2.13). Neither in univariable nor multivariable Poisson 
regression analysis, any of the other tested variables age, 
sex, WHO performance status, number of comorbidities, 
stage of disease, number of metastases and line of therapy 
were significantly associated with severe irAEs (table 2).
When analysing first- line anti- PD1- treated patients only, 
78 (14%) of the first- line anti- PD1- treated patients experi-
enced severe irAEs. A total of 44 (12%)/359 patients with 
stage IV M1c or higher had severe irAEs compared with 
33 (18%)/186 patients with stage M1b or lower, resulting 
in a unadjusted RR for severe irAEs of 0.69 (95% CI 0.44 
to 1.09) and an adjusted risk ratio (RRadj) of 0.73 (95% CI 
0.45 to 1.18), which was not significantly different. Again, 
patients with LDH >2 × ULN had a non- significantly lower 
risk of developing severe irAEs compared with those with 
normal LDH (RRadj 0.73; 95% CI 0.17 to 3.00). None 
of the other variables were significantly associated with 
severe irAEs in either univariable or multivariable analysis 
(online supplemental table 1).
In the subgroup of 565 patients with stage IV M1c/M1d 
treated in any line of systemic therapy, 12 (12%)/103 
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severe irAEs compared with 38 (11%)/360 of patients 
without any brain metastases (RR 1.10; 95% CI 0.55 to 
2.05; RRadj 1.47; 95% CI 0.77 to 2.83). In the 359 first- line 
treated patients with stage IV M1c/M1d, 11 (20%)/56 of 
patients with symptomatic brain metastases experienced 
severe irAEs, compared with 25 (10%)/250 patients 
without any brain metastases (RR 1.96; 95% CI 0.93 to 
3.89; RRadj 2.35; 95% CI 1.11 to 4.97).
Approximately 60% of patients with symptomatic brain 
metastases received steroids at baseline, compared with 
22% in all patients. Unfortunately, data on baseline 
steroid use were missing in 35% of patients. We did not 
observe a significant difference in frequency of severe 
irAEs in patients with (15.7%) and without (12.9%) base-
line steroids for patients treated in any line (RR 1.21; 
95% CI 0.69 to 2.03). Nevertheless, when we repeated 
the multivariable analyses with additional adjustment 
for baseline steroid use, the correlation between disease 
severity and severe irAEs did not change relevantly in 
patients treated in any line of therapy (RRadj for stage 
0.49; 95% CI 0.28 to 0.84) and first- line treated patients 
only (RRadj 0.46; 95% CI 0.24 to 0.90). Notably, there was 
no imbalance of baseline autoimmune disorders between 
patients with high stage (3.7%) compared with low- stage 
disease (1.8%; χ2 p value 0.231).
DISCUSSION
In the largest prospective cohort thus far, using data from 
the nationwide DMTR, we aimed to identify patient- 
related and tumour- related factors associated with the 
occurrence of severe irAEs in patients with advanced mela-
noma treated with anti- PD1. We observed that patients 
with more advanced disease (stage IV M1c or higher) had 
a significantly decreased risk of severe irAEs compared 
with patients with lower- stage disease (stage IV M1b or 
lower). None of the other factors were associated with 
the occurrence of severe irAEs. When looking at first- line 
treated patients only, we observed comparable results, 
although the association for more advanced disease was 
not significant, probably due to lower number of patients.
Recently, the high toxicity rates in early (neo)adju-
vant studies have led to the hypothesis that irAEs occur 
more frequently in patients with smaller tumour load.7 28 
Although no data on tumour volumes are available in the 
DMTR, tumour load was previously reported to be larger 
in stage M1c or higher than in patients with a lower stage 
of disease,29 pointing in the same direction. Moreover, the 
non- significant lower risk we observed in the small group 
of LDH ≥2 × ULN patients supports this. Interestingly, 
also response rates to anti- PD1 are lower in patients with 
stage IV M1c melanoma compared with lower stages,30 in 
patients with higher tumour load29 and LDH ≥2 × ULN.31 
As we and others have recently shown a correlation 
between ICI response and toxicity,32 33 one may hypoth-
esise that immunological responses in these patients are 
less strong, which might be due to the increased immuno-
suppressive tumour microenvironment in large volume 
disease.34
It is unlikely that the observed association between stage 
and severe irAEs is explained by immortal time bias, as we 





Number of patients 819 557
Age median (IQR) 65 (55–73) 67 (56–74)
Sex
  Male 472 (58%) 327 (59%)
  Female 346 (42%) 229 (41%)
WHO performance status
  0 454 (61%) 332 (64%)
  1 256 (34%) 166 (32%)
  2 36 (5%) 21 (4%)
  3 2 (0%) 2 (0%)
Number of comorbidities
  0 279 (34%) 179 (32%)
  1–2 398 (49%) 276 (50%)
  ≥3 137 (17%) 100 (18%)
Stage of disease
  Unresectable stage III 53 (7%) 41 (8%)
  IV, M1a 77 (10%) 55 (10%)
  IV, M1b 102 (13%) 90 (17%)
  IV, M1c 360 (45%) 250 (46%)
  IV, M1d 205 (26%) 109 (20%)
Symptomatic brain metastases 103 (13%) 56 (10%)
Number of metastatic sites
  0 87 (11%) 63 (12%)
  1 251 (33%) 180 (35%)
  2 222 (29%) 146 (28%)
  3 143 (19%) 84 (16%)
  4 50 (7%) 33 (6%)
  5 12 (2%) 9 (2%)
  6 1 (0%) 1 (0%)
LDH
  ≤ULN 548 (68%) 369 (67%)
  1–2 × ULN 210 (26%) 155 (28%)
  >2 × ULN 50 (6%) 27 (5%)
ICI treatment
  Nivolumab 261 (32%) 178 (32%)
  Pembrolizumab 558 (68%) 379 (68%)
Line of systemic therapy
  1 557 (68%)
  2 208 (25%)
  3 39 (5%)
  ≥4 15 (2%)
ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; 
PD1, programmed cell death 1; ULN, upper limit of normal 
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adjusted for follow- up time. Furthermore, the association 
persisted when we excluded patients who died within the 
first 3 months after treatment initiation, in which most 
toxicities occur.23 Moreover, patients with symptomatic 
brain metastases—who have a very poor prognosis—had 
a similar or even increased irAE risk when compared 
with patients with stage IV M1c without brain metastases. 
Furthermore, treatment duration did not differ signifi-
cantly between patients with and those without severe 
irAEs. However, this should be interpreted with caution as 
treatment duration is unknown in a considerable propor-
tion of patients, presumably because these patients are 
still on treatment. This may have resulted in an underes-
timation of treatment duration, which is probably more 
pronounced in patients without irAEs. Together, this 
suggests that the lower risk in patients with high- stage 
disease was not due to decreased time at risk.
Several others have tried to identify determinants of 
ICI induced toxicity. For example, baseline body mass 
index, platelet to lymphocyte ratio, absolute lympho-
cyte count and absolute eosinophil count were reported 
to be correlated with irAEs resulting from anti- PD1 
therapy.11 17 18 However, sample sizes in these studies were 
small (n<200 at risk), resulting in wide confidence inter-
vals. Most studies also report numerous other tested vari-
ables without significant predictive value.
As most autoimmune diseases display a female predom-
inance,4 sex differences in irAEs have been hypothesised, 
but reports on the association of sex with irAEs are contra-
dictory. Two cohort studies of <250 patients demonstrated 
an increased frequency of irAEs in females compared with 
males, although for frequency of grade ≥3 irAEs one of 
the studies showed no difference between both sexes.8 9 
Contrastingly, in a retrospective analysis using insurance 
data of 4438 ICI- treated patients, Kehl et al reported no 
significant difference in risk of irAEs (RRadj 1.11; 95% CI 
0.91 to 1.34) between females and males.35 Similarly, the 
frequency of severe irAEs was not higher in females in our 
cohort compared with males. With a median age of 65 
years, and with just 65 females younger than 50 years, our 
real- world cohort encompasses mainly postmenopausal 
women. As differences between male and female immune 
responses alter with age, with a supposedly important role 
of sex hormones, the discrepancy between sex- differences 
Table 2 Determinants of severe immune- related adverse events in any line anti- PD1- treated patients using both univariable 
and multivariable Poisson regression
RR
Univariable analysis Multivariable analysis
95% CI P value RRadj 95% CIadj P value
Age 1.01 0.99–1.02 0.491 1.00 0.99–1.02 0.676
Sex
  Male ref ref
  Female 1.18 0.81-1.71 0.389 1.18 0.81–1.73 0.397
WHO performance status
  0 ref ref
  1 0.52 0.53-1.24 0.363 0.96 0.62–1.49 0.845
  ≥2 0.89 0.31-2.00 0.805 1.04 0.41–2.64 0.942
Number of comorbidities
  0 ref ref
  1–2 1.27 0.83-1.98 0.277 1.16 0.73–1.86 0.529
  ≥3 1.27 0.72-2.07 0.397 1.21 0.65–2.28 0.539
Stage of disease
  Unresectable stage III/M1a/M1b ref ref
  M1c/M1d 0.57 0.39-0.85 0.046 0.63 0.41–0.94 0.026
Number of metastatic sites
  <3 ref ref
  ≥3 0.77 0.47-1.21 0.271 1.03 0.65–1.62 0.906
LDH
  ≤ULN ref ref
  1–2 × ULN 0.95 0.61-1.44 0.812 1.12 0.72–1.74 0.623
  >2 × ULN 0.43 0.10-1.14 0.148 0.65 0.20–2.13 0.475
Line of therapy 1.01 0.76-1.26 0.950 1.12 0.86–1.46 0.417
CIadj, adjusted CI; LDH, lactate dehydrogenase; ; PD1, programmed cell death 1; RR, risk ratio; RRadj, adjusted risk ratio; ULN, upper limit of 
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in autoimmune diseases compared with irAEs may be 
age- related. Besides, most severe irAEs (such as colitis) 
resemble autoimmune diseases with a sex distribution 
close to 50% (such as ulcerative colitis),36 while rheu-
matological and thyroidal irAEs are often lower grade 
and therefore in general not included in our registry. Of 
note, reports on the association of sex with ICI efficacy 
are contradictory.6 30 37
In conclusion, we demonstrated that anti- PD1- treated 
patients with more advanced disease have a lower risk of 
developing severe irAEs. No associations of sex or other 
patient- related and tumour- related factors with severe 
irAEs were found. As toxicity profiles are similar between 
tumour types, the results of this study are possibly appli-
cable to other patients treated with anti- PD1 therapy.
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